Iterum Therapeutics plc (id:6128 ITRM)
1.81 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 9:26:02 PM)
Exchange closed, opens in 1 day 12 hours
0.56 USD (0.56%)
33.09 USD (33.09%)
75.73 USD (75.73%)
31.16 USD (31.16%)
-27.60 USD (-27.60%)
-94.68 USD (-94.68%)
-99.05 USD (-99.05%)
About Iterum Therapeutics plc
Market Capitalization 44.85M
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Headquarters (address) |
Fitzwilliam Court Dublin D02 YW24 Ireland |
| Phone | 353 1 669 4820 |
| Website | https://www.iterumtx.com |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ITRM |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.808 - 2.50 |
| Market Capitalization | 44.85M |
| P/E trailing | -0.663 |
| P/E forward | -2.47 |
| Price/Book | -3.15 |
| Beta | 2.25 |
| EPS | -1.76 |
| EPS Ireland (ID:161, base:52) | 2.63 |